表紙:米国の医薬品3PL (サードパーティロジスティクス) 市場:成長・動向・COVID-19の影響・予測 (2022~2027年)
市場調査レポート
商品コード
1072163

米国の医薬品3PL (サードパーティロジスティクス) 市場:成長・動向・COVID-19の影響・予測 (2022~2027年)

UNITED STATES PHARMACEUTICAL 3PL MARKET - GROWTH, TRENDS, COVID-19 IMPACT AND FORECASTS (2022 - 2027)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 120 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.51円
米国の医薬品3PL (サードパーティロジスティクス) 市場:成長・動向・COVID-19の影響・予測 (2022~2027年)
出版日: 2022年04月28日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 120 Pages
納期: 2~3営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

米国の医薬品3PL (サードパーティロジスティクス) の市場は予測期間中に4%超のCAGRで成長すると予測されています。

米国はバイオ医薬品、ワクチン、臨床試験材料など、温度に敏感なヘルスケア製品の世界最大の市場です。血液サンプルや組織サンプル、一部の薬剤など、温度変化に敏感な物質を使用する臨床試験の件数が増加していることが、同市場の成長を促進しています。

当レポートでは、米国の医薬品3PL (サードパーティロジスティクス) の市場を調査し、市場の概要、市場影響因子の分析、技術動向、法規制環境、市場規模の推移・予測、各種区分別の内訳、主要企業のプロファイル、将来の展望などをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 技術動向
  • 政府の規制とイニシアチブ
  • 米国のEコマース市場
  • 医薬品の包装への焦点
  • 製薬業界におけるリバース/リターンロジスティクスに関する洞察
  • 業界のサプライチェーン/バリューチェーン分析
  • COVID-19:市場への影響

第5章 市場力学

  • 促進要因
  • 抑制要因
  • 市場機会
  • ポーターのファイブフォース分析

第6章 市場の分類 (金額)

  • 機能別
    • 国内輸送管理
    • 国際輸送管理
    • 付加価値倉庫・流通
  • サプライチェーン別
    • コールドチェーン
    • 非コールドチェーン

第7章 競合情勢

  • 企業プロファイル
    • DHL
    • FedEx
    • UPS
    • Kuehne+Nagel
    • DB Schenker
    • CH Robinson
    • CEVA Logistics
    • Kerry Logistics
    • Agility
    • Expeditors International of Washington Inc.

第8章 市場の将来

第9章 付録

目次
Product Code: 72614

The United States pharmaceutical third-party logistics market is expected to expand at a compound annual growth rate (CAGR) of more than 4% during the forecast period.

Due to COVID-19, the pharma supply chain is being impacted by distribution challenges created by reduced transportation capacity. Disruptions at ports, quarantined crews, and labor shortages due to lockdowns are all contributing factors. COVID-19 caused the slowdown of the new pharmaceutical product development due to material shortages, disruptions in clinical trials, and backups in FDA approval.

However, the United States is the world's largest market for temperature-sensitive healthcare products such as biopharmaceuticals, vaccines, and clinical trial materials. The rising number of clinical trials employing various temperature-sensitive materials, such as blood samples, tissue samples, and some drugs, have catalyzed the growth of the market. There are many well-established pharmaceutical companies in the United States. The pharmaceutical industry of the United States alone accounts for almost half of the global pharmaceutical market.

Furthermore, the pharmaceutical 3PL industry is bound by strict rules and regulations. For instance, warehouses and shippers of pharmaceuticals in the United States must be registered with the Food and Drug Administration (FDA). There are no exceptions, even if they are planning a short-term or emergency relationship with a 3PL provider, one must make sure they are approved to store and transport pharmaceuticals. In addition, Government regulations related to the distribution of pharmaceuticals are codified as part of the CGMPs (Current Good Manufacturing Practices), which is the best practice for health and safety of consumers.

Key Market Trends

United States Leading in Pharmaceutical Market Across the World

Despite the influence of several growing countries, the United States holds a commanding proportion of the global pharmaceutical market. The country is home to some of the world's largest pharmaceutical corporations, and American customers have access to one of the world's most advanced pharmaceutical systems.

In recent years, pharmaceutical sales revenues in the United States have accounted for about half of the global total. In 2020, the United States had five of the top ten pharmaceutical corporations in the world. AbbVie is the new number one pharmaceutical business in the United States, and its best-selling medicine is Humira. Johnson & Johnson is another American corporation that has made a global impact, with its pharmaceutical division producing a record USD 45.6 billion in 2020. Furthermore, in 2021, United States was leading in pharmaceutical sales with more than USD 555 billion, with a growth rate of 7.6% when compared to 2020. Also, the country had 46.8% of global sales in 2021 (2020: 46.8%, 2019: 46.5%).

In addition, overall pharmaceutical expenditures in the United States increased by 4.9% in 2020 compared to 2019. This rise was driven by increased utilization (a 2.9% increase) and new medications (a 1.8% increase), with price increases having little impact (a 0.3% increase).

International Trading Boosting the Market

China has been the leading supplier of medicine in the United States over the last decade, with India and Mexico contending for second and third place, respectively, depending on the year. China, India, and Mexico are the top three pharmaceutical import sources, with Canada, Germany, Italy, the United Kingdom, Israel, Spain, and Ireland filling out the top ten.

In the fiscal year ending March 31, 2021, pharmaceutical exports to India increased by 18.7% to USD 24.44 billion, owing to increasing demand for the country's generic pharmaceuticals.

Furthermore, in January 2022 export volumes of pharmaceutical goods accounted for more than USD 5.4 Billion, with a growth rate of 38% when compared to the same month in 2021. Meanwhile, the import volumes are slightly declined in 2022 by 6% compared to 2021.

Competitive Landscape

The North American pharmaceutical 3PL market is competitive and fragmented with the presence of many international players. Although the market is quite fragmented, the efforts of established firms to attain a considerable share in the target market are estimated to build healthy competition among industry players.

Some of the existing major players in the market include Deutsche Post DHL, FedEx, Kuehne + Nagel International AG, United Parcel Service Inc., C.H. Robinson Worldwide Inc., CEVA Logistics, DB Schenker, Agility Logistics, Expeditors International of Washington Inc.The pharmaceutical industry is expected to witness more acquisitions and mergers as competition increases. This industry is on the right track for continued growth.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of Study

2 RESEARCH METHODOLOGY

  • 2.1 Analysis Methodology
  • 2.2 Research Phases

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS

  • 4.1 Market Overview
  • 4.2 Technological Trends
  • 4.3 Government Regulations and Initiatives
  • 4.4 Pharmaceutical E-Commerce Market in United States
  • 4.5 Spotlight on packaging of pharmaceuticals
  • 4.6 Insights on Reverse/Return Logistics in pharma industry
  • 4.7 Industry Supply Chain/Value Chain Analysis
  • 4.8 Impact of Covid-19 on market

5 MARKET DYNAMICS

  • 5.1 Drivers
  • 5.2 Restraints
  • 5.3 Opportunities
  • 5.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 5.4.1 Bargaining Power of Suppliers
    • 5.4.2 Bargaining Power of Consumers
    • 5.4.3 Threat of New Entrants
    • 5.4.4 Threat of Substitutes
    • 5.4.5 Intensity of Competitive Rivalry

6 MARKET SEGMENTATION (Market Size By Value)

  • 6.1 By Function
    • 6.1.1 Domestic Transportation Management
    • 6.1.2 International Transportation Management
    • 6.1.3 Value-added Warehousing and Distribution
  • 6.2 By Supply Chain
    • 6.2.1 Cold Chain
    • 6.2.2 Non-cold Chain

7 COMPETITIVE LANDSCAPE

  • 7.1 Overview (Market Concentration and Major Players)
  • 7.2 Company Profiles
    • 7.2.1 DHL
    • 7.2.2 FedEx
    • 7.2.3 UPS
    • 7.2.4 Kuehne + Nagel
    • 7.2.5 DB Schenker
    • 7.2.6 C.H. Robinson
    • 7.2.7 CEVA Logistics
    • 7.2.8 Kerry Logistics
    • 7.2.9 Agility
    • 7.2.10 Expeditors International of Washington Inc.

8 FUTURE OF THE MARKET

9 APPENDIX